First chikungunya vaccine approved for persons as young as 12 years old, addressing an unmet need for chikungunya prevention for younger ...

The illness typically lasts two to seven days, but severe cases can be deadly. An affected person will have flu-like symptoms ...

The NIH announced that it is launching a phase 2 human challenge trial of AV-1, an investigational monoclonal antibody to ...

A study was conducted to assess the safety and tolerability of the tetravalent live-attenuated dengue vaccine Qdenga®, which received marketing approval in Germany in 2022. The study evaluated vaccine ...

If AV-1 shows promising results in this clinical trial, researchers may pursue further clinical evaluations of its safety and ...

Indonesia's Ministry of Health has urged the public to remain alert against dengue hemorrhagic fever during the rainy season by taking preventive ...

It's a big, germy world out there. If you want to travel with peace of mind, learn the basics of vaccines, illnesses, and ...

The Pan American Health Organization (PAHO) has issued an epidemiological alert regarding the increased risk of dengue outbreaks in the Americas, attributed to the growing circulation of the DENV-3 ...

Biological scientists have uncovered how the dengue virus uses its envelope protein to capture human plasmin from a blood meal to enhance the permeability of the mosquito midgut for infection.